Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
COMMENT 24 March 2025 New approach methodologies (NAMs) have the potential to progressively transform medicines development by reducing reliance on animal testing while increasing the relevance of nonclinical data to patients. However, achieving regulatory acceptance of NAMs demands enhanced collaboration, clear guidance and continuous, science-based adaptation of the regulatory environment to accommodate emerging innovation.
Introduction With rapid advancements in medical science and technology, development of medicines moves ever more into the direction of personalised medicine; often referred to as targeted or precision medicines. The concept of personalised medicine is not new.
Non-biological complex drugs (NBCD) are defined scientifically as not being a biological medicinal product where the active substance is not a homo-molecular structure, but consists of different closely related and often nanoparticulate structures that cannot be isolated and fully quantitated, characterized and/or described by physicochemical analytical means, where the structural elements that might impact the therapeutical performance are unknown [1].
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.